CureVac Announces Voting Results of General Meeting

^
Emittent / Herausgeber: CureVac / Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting

24.06.2025 / 22:09 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

---------------------------------------------------------------------------

CureVac Announces Voting Results of General Meeting

TÜBINGEN, Germany / BOSTON, USA - June 24, 2025 - CureVac N.V. (Nasdaq:
CVAC), a pioneering multinational biotech company developing a new class of
transformative medicines based on messenger RNA (mRNA), today announced the
voting results of the Company's Annual General Meeting.

The shareholders of the Company voted in favor of all proposals. These
proposals included the appointment of Axel Sven Malkomes as a member of the
Management Board, effective June 24, 2025. Additionally, Jean Stéphenne,
Debra Barker, Craig A. Tooman, as well as Klaus Schollmeier were reappointed
as members of the Supervisory Board, Mehdi Shahidi was appointed as a new
member of the Supervisory Board, effective June 24, 2025. KPMG Accountants
N.V. was reappointed as the external auditors for the financial year 2026.

A table containing tabulations of the votes casted is expected to be
released in the coming days.

About CureVac

CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded
in 2000 to advance the field of messenger RNA (mRNA) technology for
application in human medicine. CureVac's mRNA platform incorporates a series
of novel technologies, designed to improve the efficacy, safety and
cost-effectiveness of mRNA therapeutics aimed at resulting in enhanced
immune responses at lower doses. Additionally, CureVac has developed LNPs,
which have been optimized for indication specific use across infectious
diseases and oncology. CureVac is leveraging mRNA technology, combined with
advanced omics and computational tools, to design and develop off-the-shelf
and personalized cancer vaccine product candidates. It also develops
programs in prophylactic vaccines and in treatments that aim to enable the
human body to produce its own therapeutic proteins. Headquartered in
Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium,
Switzerland, and the U.S. Further information can be found at
www.curevac.com.

CureVac Media and Investor Relations Contact

CureVac, Tübingen, Germany

T: +49 7071 9883-0

communications@curevac.com

Forward-Looking Statements of CureVac

This press release contains statements that constitute "forward looking
statements" as that term is defined in the United States Private Securities
Litigation Reform Act of 1995, including statements that express the
opinions, expectations, beliefs, plans, objectives, assumptions or
projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE,
CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac
Corporate Services GmbH, CureVac Belgium SA and CureVac Netherlands B.V.
(the "company") regarding future events or future results, in contrast with
statements that reflect historical facts. Examples include discussion of the
potential efficacy of the company's vaccine and treatment candidates and the
company's strategies, financing plans, cash runway expectations, timing of
various milestones, the impact of restructuring, growth opportunities and
market growth. In some cases, you can identify such forward-looking
statements by terminology such as "anticipate," "intend," "believe,"
"estimate," "plan," "seek," "project," "expect," "may," "will," "would,"
"could," "potential," "intend," or "should," the negative of these terms or
similar expressions. Forward-looking statements are based on management's
current beliefs and assumptions and on information currently available to
the company. However, these forward-looking statements are not a guarantee
of the company's performance, and you should not place undue reliance on
such statements. Forward-looking statements are subject to many risks,
uncertainties and other variable circumstances, including negative worldwide
economic conditions and ongoing instability and volatility in the worldwide
financial markets, ability to obtain funding, ability to conduct current and
future preclinical studies and clinical trials, the timing, expense and
uncertainty of regulatory approval, reliance on third parties and
collaboration partners, ability to commercialize products, ability to
manufacture any products, ability to implement our pipeline strategy,
possible changes in current and proposed legislation, regulations and
governmental policies, pressures from increasing competition and
consolidation in the company's industry, the effects of the COVID-19
pandemic on the company's business and results of operations, ability to
manage growth, ability to implement, maintain and improve effective internal
controls, reliance on key personnel, reliance on intellectual property
protection and the company's and the company's collaborators' ability to
obtain, maintain, defend and enforce such intellectual property, scope of
intellectual property protection, ability to provide for patient safety,
fluctuations of operating results due to the effect of exchange rates,
delays in litigation proceedings, different judicial outcomes and other
important factors discussed under the caption "Risk Factors" in the
company's annual report on Form 20-F filed with the U.S. Securities and
Exchange Commission (the "SEC") on April 11, 2025, as such factors may be
updated form time to time in its other filings with the SEC. Such risks and
uncertainties may cause the statements to be inaccurate and readers are
cautioned not to place undue reliance on such statements. Many of these
risks are outside of the company's control and could cause its actual
results to differ materially from those it thought would occur. The
forward-looking statements included in this press release are made only as
of the date hereof. The company does not undertake, and specifically
declines, any obligation to update any such statements or to publicly
announce the results of any revisions to any such statements to reflect
future events or developments, except as required by law.

For further information, please reference the company's reports and
documents filed with the SEC. You may get these documents by visiting EDGAR
on the SEC website at www.sec.gov.

---------------------------------------------------------------------------

Veröffentlichung einer Mitteilung, übermittelt durch EQS Group.
Medienarchiv unter https://www.eqs-news.com.

Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

---------------------------------------------------------------------------

Sprache: Deutsch
Unternehmen: CureVac
Friedrich-Miescher-Str. 15
72076 Tübingen
Deutschland
EQS News ID: 2159904

Ende der Mitteilung EQS News-Service
---------------------------------------------------------------------------

°